Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines.
COVID-19
biomarkers
hypersensitivity reactions
in vitro test
vaccines
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
11
07
2022
received:
16
04
2022
accepted:
28
07
2022
pubmed:
2
8
2022
medline:
1
12
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
Hypersensitivity reactions to drugs are increasing worldwide. They display a large degree of variability in the immunological mechanisms involved, which impacts both disease severity and the optimal diagnostic procedure. Therefore, drug hypersensitivity diagnosis relies on both in vitro and in vivo assessments, although most of the methods are not well standardized. Moreover, several biomarkers can be used as valuable parameters for precision medicine that provide information on the endotypes, diagnosis, prognosis, and prediction of drug hypersensitivity development, as well on the identification of therapeutic targets and treatment efficacy monitoring. Furthermore, in the last 2 years, the SARS-CoV-2 (severe acute respiratory syndrome-coronavirus) pandemic has had an important impact on health system, leading us to update approaches on how to manage hypersensitivity reactions to drugs used for its treatment and on COVID-19 (Coronavirus disease) vaccines used for its prevention. This article reviews recent advances in these 3 areas regarding drug hypersensitivity: in vitro tools for drug hypersensitivity diagnosis, recently identified biomarkers that could guide clinical decision making and management of hypersensitivity reactions to drugs and vaccines used for COVID-19.
Identifiants
pubmed: 35912413
doi: 10.1111/all.15461
pmc: PMC9537799
doi:
Substances chimiques
Biomarkers
0
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3527-3537Informations de copyright
© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018;14:60.
Deak PE, Kim B, Adnan A, et al. Nanoallergen platform for detection of platin drug allergies. J Allergy Clin Immunol. 2019;143:1957-1960.e12.
Beyaz Ş, Akdeniz N, Yılmaz A, et al. Diagnostic workup including CD203c-based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross-reactivity in between. Allergy. 2021;76:842-852.
Prieto A, Muñoz C, Bogas G, et al. Single-dose prolonged drug provocation test, without previous skin testing, is safe for diagnosing children with mild non-immediate reactions to beta-lactams. Allergy. 2021;76:2544-2554.
You J, Sun L, Zhao Q, et al. Dynamic cytokine profiles combined with enzyme-linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome. J Am Acad Dermatol. 2021;84:814-816.
Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65:726-732.
Jakubovic BD, de Las Vecillas L, Jimenez-Rodriguez TW, Sanchez-Sanchez S, Castells M. Drug hypersensitivity in the fast lane: what clinicians should know about phenotypes, endotypes, and biomarkers. Ann Allergy Asthma Immunol. 2020;124:566-572.
Gelincik A, Demir S, Şen F, et al. Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type. Asia Pac Allergy. 2019;9:1-10.
Park S-Y, Do AR, Park T, Won S, Kim T-B. Genome-wide association study identified a novel genetic variation in HLA-DRB1 associated with drug hypersensitivity. Ann Allergy Asthma Immunol. 2022;128:335-337.
Jurado-Escobar R, Doña I, Triano-Cornejo J, et al. Genetic variants in cytosolic phospholipase A2 associated with nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema. Front Pharmacol. 2021;12:1-10.
Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021;76:1629-1639.
Barbaud A, Garvey LH, Arcolaci A, et al. Allergies and COVID-19 vaccines: an ENDA/EAACI position paper. Allergy. 2022;77:2292-2312. doi:10.1111/all.15241
Gelincik A, Brockow K, Çelik GE, et al. Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19: an EAACI position paper. Allergy. 2020;75:2775-2793.
Azzazy HME, Mansour MMH. In vitro diagnostic prospects of nanoparticles. Clin Chim Acta. 2009;403:1-8.
Gil-Ocaña V, Jimenez IM, Mayorga C, et al. Multiepitope Dendrimeric antigen-silica particle composites as Nano-based platforms for specific recognition of IgEs. Front Immunol. 2021;12:1-13.
Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep. 2018;18:77.
Brockow K. Medical algorithm: diagnosis and treatment of radiocontrast media hypersensitivity. Allergy. 2020;75:1278-1280.
Bychkova NV, Selivanov PA, Kalinina NM. Clinical implication of detecting sensitization to iodinated radiocontrast media in the basophil activation test by flow cytometry. Klin Lab Diagn. 2021;66:747-754.
Bogas G, Doña I, Dionicio J, et al. Diagnostic approach of hypersensitivity reactions to cefazolin in a large prospective cohort. J Allergy Clin Immunol Pract. 2021;9:4421-4430.e4.
Doña I, Pérez-Sánchez N, Salas M, et al. Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones. J Allergy Clin Immunol Pract. 2020;8:2707-2714.e2.
Leecyous B, Bakhtiar F, Tang MM, Yadzir ZHM, Abdullah N. Minimal agreement between basophil activation test and immunoassay in diagnosis of penicillin allergy. Allergol Immunopathol. 2020;48:626-632.
Bax HJ, Khiabany A, Stavraka C, et al. Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. Allergy. 2020;75:2069-2073.
Fernandez-Santamaria R, Bogas G, Palomares F, et al. Dendritic cells inclusion and cell-subset assessment improve flow-cytometry-based proliferation test in non-immediate drug hypersensitivity reactions. Allergy. 2021;76:2123-2134.
Mori F, Blanca-Lopez N, Caubet J, et al. Delayed hypersensitivity to antiepileptic drugs in children. Pediatr Allergy Immunol. 2021;32:425-436.
Bellón T, Rodríguez-Martín S, Cabañas R, et al. Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: concordance between lymphocyte transformation test and ALDEN. Allergy. 2020;75:956-959.
Trubiano JA, Chua KYL, Holmes NE, et al. Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. J Allergy Clin Immunol Pract. 2020;8:1142-1146.e4.
Copaescu A, Mouhtouris E, Vogrin S, et al. The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions. J Allergy Clin Immunol Pract. 2021;9:2010-2015.e4.
Xiong H, Liu T, Xiao J, et al. Warfarin-induced Stevens-Johnson syndrome with severe liver injury. J Int Med Res. 2021;49:030006052110331.
Klaewsongkram J, Buranapraditkun S, Thantiworasit P, et al. The role of in vitro detection of drug-specific mediator-releasing cells to diagnose different phenotypes of severe cutaneous adverse reactions. Allergy Asthma Immunol Res. 2021;13:896-907.
Chang L-W, Doan LT, Fields P, Vignali M, Akilov OE. The utility of T-cell clonality in differential diagnostics of acute graft-versus-host disease from drug hypersensitivity reaction. J Invest Dermatol. 2020;140:1282-1285.
Ogese MO, Lister A, Gardner J, et al. Deciphering adverse drug reactions: in vitro priming and characterization of vancomycin-specific T cells from healthy donors expressing HLA-A*32:01. Toxicol Sci. 2021;183:139-153.
Pratoomwun J, Thomson P, Jaruthamsophon K, et al. Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B*13:01. Front Immunol. 2021;12:658593.
Yoshioka M, Sawada Y, Nakamura M. Diagnostic tools and biomarkers for severe drug eruptions. Int J Mol Sci. 2021;22:7527. doi:10.3390/ijms22147527
Zhang X, Lu WS, Qin XM. Cytokines/chemokines: novel biomarkers associated with severe cutaneous adverse reactions. J Interferon Cytokine Res. 2020;40:172-181.
Giavina-Bianchi P, Patil SU, Banerji A. Immediate hypersensitivity reaction to chemotherapeutic agents. J Allergy Clin Immunol Pract. 2017;5:593-599.
Madrigal-Burgaleta R, Vazquez-Revuelta P, Marti-Garrido J, Lleonart R, Ali FR, Alvarez-Cuesta E. Importance of diagnostics prior to desensitization in new drug hypersensitivity: chemotherapeutics and biologicals. Curr Treat Options Allergy. 2020;7:1-13.
Hong DI, Madrigal-Burgaleta R, Banerji A, Castells M, Alvarez-Cuesta E. Controversies in allergy: chemotherapy reactions, desensitize, or Delabel? J Allergy Clin Immunol Pract. 2020;8:2907-2915.e1.
Caiado J, Castells MC. Drug desensitizations for chemotherapy: safety and efficacy in preventing anaphylaxis. Curr Allergy Asthma Rep. 2021;21:22-24.
Silver J, Garcia-Neuer M, Lynch D-M, Pasaoglu G, Sloane DE, Castells M. Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract. 2020;8:1668-1680.e2.
Moñino-Romero S, de Las Vecillas L, Alenazy LA, et al. Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients. J Allergy Clin Immunol Pract. 2020;8:2085-2088.e10.
Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol. 2015;136:236-244.
Manson LEN, van den Hout WB, Guchelaar HJ. Genotyping for HLA risk alleles to prevent drug hypersensitivity reactions: impact analysis. Pharmaceuticals. 2022;15:1-12.
Krismawati H, Irwanto A, Pongtiku A, et al. Validation study of hla-b* 13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. PLoS Negl Trop Dis. 2020;14:1-11.
Mitsui Y, Shinkuma S, Nakamura-Nishimura Y, et al. Serum soluble OX40 as a diagnostic and prognostic biomarker for drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol Pract. 2022;10:558-565.e4.
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55:105955.
Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021;54:1636-1651.
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol. 2020;34:e212-e213.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416.
Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887-897.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99-111.
Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. JAMA. 2021;325:1575.
Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824-1835.
Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224-233.
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181-192.
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. Jama. 2021;325:780-781.
Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52:910-941.
Klimek L, Jutel M, Akdis CA, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - an EAACI-ARIA position paper. Allergy. 2021;76:1624-1628.
Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? BJA Br J Anaesth. 2021;126:e106-e108.
Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51:861-863.
Stone CA, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533-1540.e8.
Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021;9:670-675.
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907-922.
Zhou ZH, Stone CA, Jakubovic B, et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9:1731-1733.e3.
Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9:3546-3567.
Banerji A, Wolfson AR, Robinson LB, et al. COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy. Allergy. 2022;77:1048-1051.
Borgsteede SD, Geersing TH, Tempels-Pavlica Ž. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76:1941-1942.
Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021;76:2605-2607.
Labella M, Céspedes JA, Doña I, et al. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine. Allergy. 2021;77:2067-2062.
Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy. 2021;76:2916-2920.